Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Psyence Biomedical ( (PBM) ) has provided an update.
Psyence Biomedical Ltd. announced that its subsidiary, Psyence Australia Pty Ltd, has entered into a Master Services Agreement with Southern Star Research Pty Ltd to conduct a Phase IIb clinical trial for its psilocybin drug candidate, PEX010. This agreement, finalized on May 21, 2025, marks a significant step in evaluating PEX010 for treating adjustment disorder in cancer patients. Southern Star Research will provide comprehensive contract research services, including trial management, data management, regulatory support, and patient recruitment. This collaboration is expected to enhance Psyence’s operational capabilities and strengthen its position in the psychedelic therapy market.
More about Psyence Biomedical
Psyence Biomedical Ltd. operates in the biotechnology industry, focusing on psychedelic-assisted therapy. The company is involved in developing psilocybin-based treatments, particularly targeting adjustment disorders in cancer patients.
Average Trading Volume: 85,491
Technical Sentiment Signal: Sell
Current Market Cap: $3.04M
For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.